Boston Scientific Corporation Provides Data At Heart Rhythm 2026 Highlight Key Boston Scientific Therapies

Boston Scientific Corporation announced data supporting use of the company's FARAPULSE? Pulsed Field Ablation (PFA) Platform and WATCHMAN? Left Atrial Appendage Closure (LAAC) technologies.

All data were presented at Heart Rhythm 2026, the annual meeting of the Heart Rhythm Society, held in Chicago from April 24-26. Results from the AVANT GUARD clinical trial of FARAPULSE? PFA The randomized AVANT GUARD clinical trial met all safety and effectiveness endpoints and demonstrated statistical superiority of PFA over anti-arrhythmic drugs (AADs) with significantly higher primary effectiveness.

The trial is the first randomized pivotal study to evaluate patients with persistent atrial fibrillation (AF) who had not previously been treated for their condition ? a historically understudied, high-risk population. Patients were randomized or assigned to receive pulmonary vein isolation (PVI) and left atrial posterior wall isolation (PWI) using the FARAWAVE?

PFA Catheter or given AADs for treatment. Results were simultaneously published in The New England Journal of Medicine. Key findings from the trial: · PFA achieved superiority over AADs with a primary effectiveness rate of 56.0% at 12 months compared to 30.1% in the AAD group.

The primary safety endpoint was met with major adverse event rate of 5.1% at 12 months. Significantly more patients in the PFA group (51.7%) were free from atrial arrhythmia recurrence at 12 months, compared to 32.2% in the AAD group. Results from the feasibility study of the FARAFLEX?

PFA Catheter: The single-arm, ELEVATE-PF feasibility trial is examining the safety and effectiveness of the FARAFLEX PFA Catheter, a novel, high-density large focal map-and-ablate catheter designed to treat complex arrhythmias, in patients with paroxysmal and persistent AF. The trial enables ongoing PFA dosing and workflow refinements based on a study design incorporating prospective high-density remapping, analyzing patients sequentially in three groups ? feasibility, improved and optimized.

Key findings from this ongoing trial: · With workflow improvements, PVI durability ? the permanence of an ablation lesion over time ? increased from 80.4% on a per-vein basis in the feasibility group (n=13) to 96.4% in the optimized group (n=34).

Within the optimized group, PVI durability in patients with persistent AF was 95.6% at two months (n=17). There were no reports of stroke, pulmonary vein stenosis, hemolysis or coronary spasm. Clinical outcomes associated with real-world concomitant PFA and LAAC interventions: Prospective, interim, real-world evidence from ALIGN-AF, a multi-center sub-study of the DISRUPT-AF registry, reinforced that concomitant procedures combining the FARAWAVE PFA Catheter and the WATCHMAN FLX?

Pro LAAC Device could be performed safely without compromising acute procedural success. The study, which includes 122 patients at 12 sites with 24 physicians performing the procedures, assessed peri-device leaks between 45 and 90 days following implant and will assess arrhythmia recurrence at six and 12 months. Key findings from available data at three months: · Ablation with the FARAWAVE PFA Catheter achieved a 100% (n=122/122) acute success rate.

Ablation parameters such as lesion sets and procedure duration were consistent with those observed in standalone PFA procedures. LAAC with the WATCHMAN FLX Pro implant also achieved 100% (n=119/119) procedural success and 90.6% (n=96/106) complete LAA closure at a mean of 66 days with no clinically relevant leaks or device-related thrombus reported. Sub-analysis of the CHAMPION-AF clinical trial in patients with or without prior ablation: A sub-analysis of the CHAMPION-AF trial studied LAAC therapy with the WATCHMAN FLX implant compared to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with and without prior ablation for non-valvular atrial fibrillation (NVAF).

The analysis included 1,434 patients who had a cardiac ablation for AF prior to randomization and 1,565 patients who did not have a previous ablation. The results highlighted that for patients in both arms of the sub-analysis, the device provided statistically significant protection from non-procedural bleeding and had similar efficacy to NOACs. Key findings from the sub-analysis: · The WATCHMAN FLX device provided statistically significant protection from non-procedural bleeding, including major and clinically relevant non-major bleeding (CRNMB), compared to NOACs in patients who had a prior ablation (9.0% vs.

17.0%) and in patients with no prior ablation (12.8% vs. 20.8%). CRNMB is defined within the trial as life-impacting non-major bleeds that require medical intervention, hospitalization or an increased level of care.

The WATCHMAN FLX device had similar efficacy to NOACs for the occurrence of stroke, cardiovascular or unexplained death, or systemic embolism, regardless of whether they had a prior ablation (3.9% for both the device and NOACs in patients with prior ablation; 7.5% for the device group vs. 5.7% for the NOAC group in patients with no prior ablation). Long-term outcomes after LAAC therapy in patients not eligible for anticoagulation: Five-year follow-up data from the ASAP-TOO trial provided evidence on the legacy WATCHMAN LAAC device (n=284) or the WATCHMAN FLX LAAC device (n=20) compared to a single antiplatelet (SAPT) medication or no medication in reducing the risk of ischemic stroke or systemic embolism in patients with NVAF who were deemed unsuitable for oral anticoagulation (OAC) medication.

While the findings contribute new clinical data on LAAC and stroke protection, interpretation is limited as the trial ended early due to slow enrollment driven by physician preference for the device over SAPT/no medication, not safety-related factors, and variability in long-term follow-up. Key findings from the trial: · There was a lower rate of occurrence of stroke or systemic embolism with an LAAC device compared to the control group (7.8% vs. 11.4%).

LAAC therapy was associated with significantly fewer disabling strokes compared to the control group (1.1% vs. 3.8%). The device group had a rate of 1.0% for all-cause death, ischemic stroke, systemic embolism or device- or procedure-related events requiring open cardiac surgery or major endovascular intervention within discharge or seven days.

Results from the investigator-sponsored PRAETORIAN DFT study of the EMBLEM? MRI Subcutaneous Implantable Defibrillator (S-ICD) were also presented as a late-breaking clinical trial, meeting the primary endpoint. Findings from the trial achieved non-inferiority in the likelihood of failed therapy when omitting defibrillation testing as guided by the PRAETORIAN score ?

an estimate of successful delivery of life-saving therapy ? in patients receiving the device for the first time.